AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32780600 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard monitoring)
Number of subjects: 0
Study 32780661 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRT (43.5 Gy in 15 fractions over 3 weeks with a boost of 8.7 Gy in three daily fractions)
Number of subjects: 734
Study 32780661 — intervention group
Group type: COMPARATOR
Intervention: CFRT (50 Gy in 25 fractions over 5 weeks with a boost of 10 Gy in five fractions over 1 week)
Number of subjects: 734
Study 32780660 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily)
Number of subjects: 275
Study 32780660 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 275
Study 32780725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping Beauty-engineered CAR T cells
Number of subjects: 13
Study 32780845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 187
Study 32780846 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel, CD19-28z CAR T therapy, B-cell maturation antigen targeting CAR T cells)
Number of subjects: 83
Study 32780846 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 83
Study 32780964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency extension (LFE) setting
Number of subjects: 42
Study 32780964 — intervention group
Group type: COMPARATOR
Intervention: Normal setting
Number of subjects: 42
Study 32780981 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training using a novel assistive gait training device, 3 sessions a week for 8 weeks
Number of subjects: 11
Study 32780981 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training using a novel assistive gait training device
Number of subjects: 11
Study 32781244 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation cohort (n=644)
Number of subjects: 1113
Study 32781244 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (n=469)
Number of subjects: 1113
Study 32781244 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for SRF in derivation cohort
Number of subjects: 1113
Study 32781287 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving distance (operationalized as a continuous variable)
Number of subjects: 1136
Study 32781287 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving distance (operationalized as a dichotomous variable: <100 miles vs 100+ miles)
Number of subjects: 1136
Study 32781287 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host-disease
Number of subjects: 1136
Study 32781287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 1136
Study 32781287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of Internet access
Number of subjects: 1136
Study 32781286 — intervention group
Group type: EXPERIMENTAL
Intervention: Support, Educate, Empower (SEE) personalized glaucoma coaching program
Number of subjects: 39
Study 32781527 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gemcitabine with cisplatin
Number of subjects: 0
Study 32781527 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitor of fibroblast growth factor receptor 2 (FGFR2)
Number of subjects: 0
Study 32781527 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic drugs
Number of subjects: 0
Study 32781541 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) plus IT-MTX (intrathecal methotrexate) 12 mg, six cycles of R-CHOP and four fixed doses of IT-MTX.
Number of subjects: 33
Study 32781883 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed using the 8-Item Patient Health Questionnaire (score ≥10 indicating clinically relevant depressive symptoms) at baseline and 3 months.
Number of subjects: 1243
Study 32781883 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status measured by Peripheral Artery Questionnaire and EQ-5D Visual Analogue Scale at baseline and 3, 6, and 12 months.
Number of subjects: 1243
Study 32782084 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine-type stimulant positive patients
Number of subjects: 396
Study 32782084 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine-type stimulant negative patients
Number of subjects: 396
Study 32782818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric size phlebotomy tubes
Number of subjects: 200
Study 32782818 — intervention group
Group type: COMPARATOR
Intervention: Adult size phlebotomy tubes
Number of subjects: 200
Study 32785569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium during volatile anesthesia (Group I)
Number of subjects: 126
Study 32785569 — intervention group
Group type: COMPARATOR
Intervention: No muscle relaxant during volatile anesthesia (Group II)
Number of subjects: 126
Study 32785680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-pyruvate magnetic resonance imaging (MRI)
Number of subjects: 0
Study 32785680 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ T effector memory cells
Number of subjects: 0
Study 32785680 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell sequencing of circulating T cells
Number of subjects: 0
Study 32785820 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal tau accumulation in MCI subjects
Number of subjects: 23
Study 32785820 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI atrophy in MCI subjects
Number of subjects: 23
Study 32785820 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal FTP accumulation
Number of subjects: 23
Study 32785820 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FTP uptake
Number of subjects: 23
Study 32785881 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 μg/g + betamethasone dipropionate 0.5 mg/g (Cal/BD) cutaneous foam
Number of subjects: 340
Study 32785881 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 340
Study 32786149 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal
Number of subjects: 88
Study 32786149 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids and/or tacrolimus treatment for rejection
Number of subjects: 88
Study 32787449 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib
Number of subjects: 0
Study 32787913 — intervention group
Group type: EXPERIMENTAL
Intervention: Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
Number of subjects: 32
Study 32788120 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised thromboprophylaxis protocol with augmented LMWH dosing, anti-Xa measurements, and twice-weekly ultrasonography screening for DVT
Number of subjects: 72
Study 32788120 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised thromboprophylaxis protocol
Number of subjects: 72
Study 32788149 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 250
Study 32788149 — intervention group
Group type: EXPERIMENTAL
Intervention: WebApp
Number of subjects: 250
Study 32788149 — intervention group
Group type: COMPARATOR
Intervention: Information-only control
Number of subjects: 250
Study 32788205 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-164 (a second-generation investigational antibody-drug conjugate comprised of a human anti-GCC mAb conjugated to DGN549)
Number of subjects: 0
Study 32788687 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 treatment
Number of subjects: 17
Study 32788687 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 withdrawal (E2-WD)
Number of subjects: 17
Study 32788687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle baseline
Number of subjects: 17
Study 32788708 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I interferon treatment
Number of subjects: 0
Study 32788708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 32789526 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoreceptor-related imaging features (ONL, IS, OS thickness)
Number of subjects: 89
Study 32789526 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoreceptor-related imaging features (OS thickness)
Number of subjects: 89
Study 32789526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipsoid zone (EZ) loss-to-GA boundary distance
Number of subjects: 89
Study 32789526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated B-scan segmentation
Number of subjects: 89
Study 32789526 — intervention group
Group type: EXPERIMENTAL
Intervention: Macula-wide photoreceptor laminae thinning
Number of subjects: 89
Study 32789591 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent abemaciclib
Number of subjects: 281
Study 32789591 — intervention group
Group type: COMPARATOR
Intervention: Real-world single-agent chemotherapy (capecitabine, gemcitabine, eribulin, or vinorelbine)
Number of subjects: 281
Study 32789800 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular micro-bypass stent(s) implantation (iStent or iStent inject) with phacoemulsification
Number of subjects: 47
Study 32789967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally once daily
Number of subjects: 35
Study 32790018 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo novel missense variants in RPS20
Number of subjects: 2
Study 32790648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicotinamide riboside (NR) for 5 to 9 days
Number of subjects: 19
Study 32790648 — intervention group
Group type: COMPARATOR
Intervention: MitoDAMP-treated PBMCs
Number of subjects: 19
Study 32790733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 2512
Study 32790733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine alone
Number of subjects: 2512
Study 32790733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine with azithromycin
Number of subjects: 2512
Study 32790733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 2512
Study 32790733 — intervention group
Group type: COMPARATOR
Intervention: Neither drug
Number of subjects: 2512
Study 32791124 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of conjugated estrogen (Premarin cream) twice weekly for 12 weeks
Number of subjects: 0
Study 32791158 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection pressure monitoring during PNB
Number of subjects: 37
Study 32791158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraneural needle tip location
Number of subjects: 37
Study 32791158 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow rate (9.6 mL/min)
Number of subjects: 37
Study 32791158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical roots (intraneural)
Number of subjects: 37
Study 32791158 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall injection pressure monitoring
Number of subjects: 37
Study 32791423 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 homozygotes
Number of subjects: 564
Study 32791423 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers
Number of subjects: 564
Study 32791423 — intervention group
Group type: EXPERIMENTAL
Intervention: CMBs
Number of subjects: 564
Study 32791523 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI as a third agent
Number of subjects: 19462
Study 32791523 — intervention group
Group type: COMPARATOR
Intervention: NNRTI or PI
Number of subjects: 19462
Study 32791715 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional near infrared spectroscopy
Number of subjects: 120
Study 32791715 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion in the Heart meridian
Number of subjects: 120
Study 32791715 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion in the Lung meridian
Number of subjects: 120
Study 32791868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D optical surface imaging
Number of subjects: 19
Study 32792226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human arylsulfatase A (rhASA) at 10, 30, or 100 mg every other week for 38 weeks (n=6 per cohort)
Number of subjects: 24
Study 32792226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human arylsulfatase A (rhASA) at 100 mg (cohort 4, n=6)
Number of subjects: 24
Study 32792226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human arylsulfatase A (rhASA) at 100 mg
Number of subjects: 24
Study 32792335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass screening and eradication
Number of subjects: 7616
Study 32792350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1493
Study 32792350 — intervention group
Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 1493
Study 32792350 — intervention group
Group type: COMPARATOR
Intervention: Other types of imaging
Number of subjects: 1493
Study 32792350 — intervention group
Group type: COMPARATOR
Intervention: No imaging reported
Number of subjects: 1493
Study 32792421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 32792421 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 0
Study 32792436 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 462
Study 32792436 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM)
Number of subjects: 462
Study 32792436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 462
Study 32792456 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy Sensory Instrument for Cognition, Consciousness and Awareness (MuSICCA)
Number of subjects: 80
Study 32792659 — intervention group
Group type: EXPERIMENTAL
Intervention: UBE3A pathogenic variants and imprinting defects (IPD)
Number of subjects: 250
Study 32792659 — intervention group
Group type: EXPERIMENTAL
Intervention: UBE3A pathogenic variants (truncating mutations)
Number of subjects: 250
Study 32792659 — intervention group
Group type: EXPERIMENTAL
Intervention: Deletion encompassing UBE3A and other genes
Number of subjects: 250
Study 32792659 — intervention group
Group type: EXPERIMENTAL
Intervention: Deletion length (class I vs. II)
Number of subjects: 250
Study 32792991 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment after 12 weeks
Number of subjects: 100
Study 32792991 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobiological response assessment using PET, fMRI, and EEG
Number of subjects: 100
Study 32792991 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to duloxetine if non-response at week 4 or intolerable side effects
Number of subjects: 100
Study 32793403 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox film-coated tablets (FCT)
Number of subjects: 53
Study 32793815 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripts for discussing stopping cancer screening and information on patient's 10-year life expectancy provided to primary care providers (PCPs)
Number of subjects: 90
Study 32793815 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripts for discussing stopping cancer screening and information on patient's 10-year life expectancy provided to PCPs
Number of subjects: 90
Study 32793850 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity (FI)
Number of subjects: 683
Study 32793850 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal food security
Number of subjects: 683
Study 32793850 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity (FI) with meal plans (MP)
Number of subjects: 683
Study 32793850 — intervention group
Group type: COMPARATOR
Intervention: Food security (FS) with meal plans (MP)
Number of subjects: 683
Study 32794142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate (0.5-2.0 mg/kg)
Number of subjects: 22
Study 32794560 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of severe RSV ARTI
Number of subjects: 630
Study 32794560 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers associated with respiratory sequelae
Number of subjects: 630
Study 32794560 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterization of viral load and host immune response
Number of subjects: 630
Study 32794560 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic, proteomic, metabolomic and epigenetic signatures
Number of subjects: 630
Study 32794560 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity scores
Number of subjects: 630
Study 32794574 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV associated hospitalization in the first year of life
Number of subjects: 10000
Study 32794574 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cohort of 1000 infants
Number of subjects: 10000
Study 32795224 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab, Ibrutinib, and Venetoclax
Number of subjects: 50
Study 32795349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus CapeOx (200 mg IV of sintilimab and 1000 mg/m2 of capecitabine and oxaliplatin)
Number of subjects: 20
Study 32795349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus CapeOx
Number of subjects: 20
Study 32795990 — intervention group
Group type: EXPERIMENTAL
Intervention: PromMera app intervention for 12 weeks
Number of subjects: 154
Study 32795990 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 154
Study 32795996 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 32795996 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated CPAP pressure
Number of subjects: 0
Study 32795996 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography and bronchoscopy
Number of subjects: 0
Study 32795996 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest computed tomography
Number of subjects: 0
Study 32796254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise (65% V˙O2max) for 1 hour
Number of subjects: 14
Study 32796254 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (rest)
Number of subjects: 14
Study 32796254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise (65% V˙O2max)
Number of subjects: 14
Study 32796254 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 14
Study 32796418 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners who suffered EAMC
Number of subjects: 98
Study 32797064 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compacted LV mass (median 14.0 [interquartile range 12.6-16.0] g/m2)
Number of subjects: 60
Study 32797064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of non-compacted to compacted LV mass (mean 25.6 ± 4.2%)
Number of subjects: 60
Study 32797064 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of non-compacted LV volume (mean 17.6 ± 2.9%)
Number of subjects: 60
Study 32797064 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of non-compacted LV volume
Number of subjects: 60
Study 32797064 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of right-to-left shunt (RLS)
Number of subjects: 60
Study 32797101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administrations (MDAs) and reactive focal mass drug administrations (rfMDAs) with annual indoor residual spraying (IRS) and long-lasting insecticidal nets (LLINs)
Number of subjects: 48448
Study 32797101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administrations (MDAs)
Number of subjects: 48448
Study 32797101 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I interventions
Number of subjects: 48448
Study 32797101 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall project interventions
Number of subjects: 48448
Study 32797734 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 3305
Study 32798130 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant CAMLs present at T3 (30 days after CRT completion)
Number of subjects: 39
Study 32798473 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with haematological malignancies
Number of subjects: 536
Study 32798522 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SDB
Number of subjects: 250
Study 32798522 — intervention group
Group type: COMPARATOR
Intervention: Patients without SDB
Number of subjects: 250
Study 32798522 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Sleep Apnea (CSA)
Number of subjects: 250
Study 32798522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 250
Study 32798522 — intervention group
Group type: EXPERIMENTAL
Intervention: History of transient ischemic attack or stroke
Number of subjects: 250
Study 32798522 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postoperative MPCs
Number of subjects: 250
Study 32798585 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV-coinfected
Number of subjects: 2641
Study 32798585 — intervention group
Group type: COMPARATOR
Intervention: HCV-monoinfected
Number of subjects: 2641
Study 32799036 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment in frontline therapy
Number of subjects: 339
Study 32799072 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow habituation phenotype
Number of subjects: 229
Study 32799072 — intervention group
Group type: COMPARATOR
Intervention: Rapid habituation phenotype
Number of subjects: 229
Study 32799356 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 718
Study 32799356 — intervention group
Group type: COMPARATOR
Intervention: Extended duration antibiotics
Number of subjects: 718
Study 32799356 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 718
Study 32799568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 0
Study 32799695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive Breastfeeding (EBF)
Number of subjects: 110
Study 32799695 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominant Breastfeeding (PBF)
Number of subjects: 110
Study 32799695 — intervention group
Group type: COMPARATOR
Intervention: Partial Breastfeeding (PartBF)
Number of subjects: 110
Study 32800064 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hand washing (7-10 times/day)
Number of subjects: 6273
Study 32800064 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hand washing (>10 times/day)
Number of subjects: 6273